In contrast, PBM therapy, which is emerging as a new treatment for glaucoma, induces the inhibition of nitric oxide in the electron transport system and promotes an increase in the activity of CCO, reduces oxidative stress and inflammatory reactions in the eye, and increases energy production in the cells (Figure 3). The gene discussed is RYR1; the disease is glaucoma.